Oncology
Oncology Vol 32 No 4
Volume: 32
Issue: 4
Oncology Vol 32 No 3
Volume: 32
Issue: 3
Oncology Vol 32 No 2
Volume: 32
Issue: 2
Oncology Vol 32 No 1
Volume: 32
Issue: 1
Oncology Vol 31 No 12_Suppl_1
Volume: 31
Issue: 12_Suppl_1
Oncology Vol 31 No 12
Volume: 31
Issue: 12
Oncology Vol 31 No 11
Volume: 31
Issue: 11
Oncology Vol 31 No 10
Volume: 31
Issue: 10
Oncology Vol 31 No 9
Volume: 31
Issue: 9
Oncology Vol 31 No 8
Volume: 31
Issue: 8
Oncology Vol 31 No 7
Volume: 31
Issue: 7
Oncology Vol 31 No 6
Volume: 31
Issue: 6
Oncology Vol 31 No 5
Volume: 31
Issue: 5
Oncology Vol 31 No 4
Volume: 31
Issue: 4
Oncology Vol 31 No 3
Volume: 31
Issue: 3
Oncology Vol 31 No 2
Volume: 31
Issue: 2
Oncology Vol 31 No 1
Volume: 31
Issue: 1
ONCOLOGY Vol 30 No 12_Suppl_2
Volume: 30
Issue: 12_Suppl_2
Oncology Vol 30 No 12
Volume: 30
Issue: 12
Oncology Vol 30 No 11
Volume: 30
Issue: 11
Oncology Vol 30 No 10
Volume: 30
Issue: 10
Oncology Vol 30 No 9
Volume: 30
Issue: 9
Oncology Vol 30 No 8
Volume: 30
Issue: 8
Oncology Vol 30 No 7
Volume: 30
Issue: 7
Oncology Vol 30 No 6
Volume: 30
Issue: 6
Oncology Vol 30 No 5
Volume: 30
Issue: 5
Oncology Vol 30 No 4_Suppl_1
Volume: 30
Issue: 4_Suppl_1
Oncology Vol 30 No 4
Volume: 30
Issue: 4
Oncology Vol 30 No 3
Volume: 30
Issue: 3
Oncology Vol 30 No 2
Volume: 30
Issue: 2
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
2
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
3
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
4
Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL
5
